{
  "docId": "019de076-e0bc-7319-b2fa-5eeb46bcf895",
  "docSlug": "439c1d555948cf75a9b0a41f96565740",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 29,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "key_messages",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e0bc-7319-b2fa-5eeb46bcf895/15",
  "deckHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895",
  "deckJsonHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895.json",
  "deckAnchorHref": "/decks/019de076-e0bc-7319-b2fa-5eeb46bcf895#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.035,
        "w": 0.842,
        "x": 0.048,
        "y": 0.628
      },
      "kind": "list",
      "text": "Preparations underway with global CRO in preparation for Phase 3 study implementation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c6b57fa-b4ed-45be-a2ce-2d1a36f0ba2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.688,
        "x": 0.048,
        "y": 0.688
      },
      "kind": "list",
      "text": "Development and commercial partnership discussions remain ongoing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "638606d8-515f-468f-8653-520be5d5a831",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.916,
        "x": 0.085,
        "y": 0.408
      },
      "kind": "list",
      "text": "Other regulatory designations protected and maintained (QIDP, ODD, Fast-Track, potential for Breakthrough Therapy)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ada5e63-5303-4355-ab87-5f337aacf7ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.115,
        "w": 0.929,
        "x": 0.048,
        "y": 0.468
      },
      "kind": "list",
      "text": "In February 2024, reached agreement with FDA on a single Phase 3 Registration Trial in support of an NDA for the treatment of invasive aspergillosis in patients with limited treatment options (the “ORALTO” Trial)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97047343-3f3c-4488-b944-13111805ef0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.115,
        "w": 0.904,
        "x": 0.048,
        "y": 0.198
      },
      "kind": "list",
      "text": "Near-term development strategy refined to narrow initial target indication: treatment of invasive aspergillosis in patients with limited treatment options (azole-intolerant, azole-resistant, or not effectively managed with an azole)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dab0691f-912a-41cf-9cfd-2a319c319755",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.488,
        "x": 0.085,
        "y": 0.348
      },
      "kind": "list",
      "text": "Potential registration through leveraging LPAD pathway",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e90ffce1-98af-4cc1-bdcc-db0e852fe613",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.563,
        "x": 0.048,
        "y": 0.075
      },
      "kind": "title",
      "text": "MAT2203 Regulatory and Development Strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee1ef1a8-095d-43b1-9b5a-175be8237f74",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "2dc1cdd3-bc2e-479e-af12-21042fa4f60a",
      "evidence": "The slide contains a list/bullet component with several items, indicating a list presentation.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 15,
      "beatId": "0d239d69-38a8-4fc3-95d9-96cdcbf4c62f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slide 15 outlines MAT2203's regulatory and development strategy.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}